US 11,918,634 B2
Method for activating T cells for cancer treatment
Jung Ho Kim, Seoul (KR); and Beom Seok Kim, Seoul (KR)
Assigned to GOOD T CELLS, INC., Seoul (KR)
Appl. No. 16/638,055
Filed by GOOD T CELLS, INC., Seoul (KR)
PCT Filed Aug. 10, 2018, PCT No. PCT/KR2018/009224
§ 371(c)(1), (2) Date Jun. 25, 2020,
PCT Pub. No. WO2019/031938, PCT Pub. Date Feb. 14, 2019.
Claims priority of application No. 10-2017-0101800 (KR), filed on Aug. 10, 2017.
Prior Publication US 2021/0009952 A1, Jan. 14, 2021
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); C12N 15/869 (2006.01)
CPC A61K 39/0011 (2013.01) [A61K 35/17 (2013.01); A61K 38/162 (2013.01); A61K 38/1774 (2013.01); C12N 5/0636 (2013.01); C12N 15/869 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/24 (2013.01); C12N 2501/25 (2013.01); C12N 2502/1107 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1121 (2013.01); C12N 2502/1157 (2013.01)] 6 Claims
 
1. A method for preventing or treating cancer, comprising a step of administering to a target individual an antigen-presenting cell loaded with an Epstein-Barr virus (EBV)-positive cancer-specific tumor antigen neoepitope consisting of any one of SEQ ID NOs: 1, 5, 63, 99 and 136.